

Follow-on Biologics Workshop Tweets

On February 4, 2014, the FTC's Office of Policy and Planning hosted a one-day workshop about follow-on biologics in Washington, D.C. FTC staff ~~live~~ tweeted the event from the Commission's @FTC Twitter account.

The following is a transcript of those tweets in chronological order for ease of reading. All Tweets, without handles redacted, remain publicly available on the @FTC account for as long as Twitter allows.

Promotional tweets

Happening at 8:30am: FTC follow on biologics workshop: Impact of recent legislation & regulatory naming proposals on #competition. #FTC

Want to learn more about what follow on biologics are & why they're important? Read this blog post: <http://go.usa.gov/BDC3> #FTCfob

Watch the FTC follow on biologics here: <http://bit.ly/1bgdyNZ> #FTCfob

Watch the FTC's follow on biologics workshop here at 8:30am ET: <http://bit.ly/1bgdyNZ> #FTCfob

Harvard's Aaron Kesselheim now up: Lessons for regulation of biologics from experiences w/small molecule drugs. #FTCfob

Kesselheim explains Hatch-Waxman market outcomes from 1980. By 2012, 84% prescriptions filled w/generic drugs (up from 19%). #FTCfob

Barriers to generic drug: ?s abt safety & comparability; brand marketing; & physicians not knowing about costs Kesselheim. #FTCfob

Kesselheim says the state drug product selection laws are part of the success of generic drugs. #FTCfob

Science will continue to evolve in this space, says Kesselheim at the #FTCfob workshop. pic.twitter.com/Y2CQ91AbQk

Emily Shaefer, ThinkFDA explains rigorous FDA review process for biosimilars &
pim 4(w)6(o)>>BDC -10(4(w)6(1C -61.08 -1.22 Td ()Tj[(E)-1(mily)4(Sh)-4(a

As FTC's workshop on biologics continues before lunch break, we're switching gears to tweet about privacy, data security hearing. #FTCfob

We'll be back to tweeting the #FTCfob workshop after lunch. Catch up w/ us at 1:35pm. Note: You may need to refresh your browser then.

We're jumping back into our workshop on follow biologics! Agenda + info:
<http://go.usa.gov/BjSB> Webcast: <http://bit.ly/1bgdyNZ> #FTCfob

Reminder- you may need to refresh ur browser! Now, FTC's Elizabeth Jex provides brief overview of afternoon presentations & panel. #FTCfob

Now up, an intro to drug naming by Angela Long & Morris, U.S. Pharmacopeia. #FTCfob

Want to know more about our speakers? You can find bios for FTC staff & panelists here:
<http://go.usa.gov/BDvG#FTCfob>

Helen Hartman, Pfizer, presentation is looking into the future of the biosimilar landscape.
#FTCfob

Hartman: Distinguishable identifier (dif nonproprietary or trade name) essential to safeguard safety & is supported by reg science.#FTCfob

Happening now, Emily Alexander, AbbVie, discussing the reference biologic perspectives on naming. #FTCfob

Emily Alexander discusses the limitations of using distinct brand names at #FTCfob workshop.
pic.twitter.com/AcqC2Vo3Qc

Alexander says all patients deserve to have access to these ~~same~~ life-saving biologic therapies, including biosimilars. #FTCfob

Alan Lotvin, CVS, gives us the customer perspective on consumer safety, access, & interchangeable biosimilar #competition. #FTCfob

Biologic patent expirations create new possibilities for #competition from biosimilars & interchangeable biologics Lotvin #FTCfob

Lotvin says CVS believes providing biosimilars w/unique names will create barriers to substitution. #FTCfob

Hi! If we didn't mention it yet, transcript & archive will post to
[http://FTC.g\(dn'\)!rhdes fo10ty1D2\(r\)10\(93\)8\(f\)C79TT0 298.44 Tf \[-2\(5i\)141-2\(s2\(TCTd f\)-4\(o#\)3\(F\)4\(T](http://FTC.g(dn')!rhdes fo10ty1D2(r)10(93)8(f)C79TT0 298.44 Tf [-2(5i)141-2(s2(TCTd f)-4(o#)3(F)4(T)

Panelists continue to discuss how unique or distinguishable USANs ~~or~~ proprietary names affect competition. #FTCfob

Panelists at #FTCfob workshop discuss naming & pharmacovigilance.
pic.twitter.com/X9vfBx1qff

Closing Remarks